OmegaGenesis, a nanotechnology company, and The Department of Surgery at The University of Arizona College of Medicine, have signed an agreement to collaborate on potential remedies to address diabetic foot ulcers.
Subscribe to our email newsletter
The agreement includes joint work in support of potential remedies and to identify effective ways to provide information and education to medical professionals and patients globally.
The University of Arizona (UA) is collaborating with OmegaGenesis to address common goals in testing remedies to address foot ulcers, providing education and in reducing amputations related to foot ulcers.
Oostur Raza, CEO of OmegaGenesis, said: “Through this collaboration we hope to reduce the number of amputations that result from diabetic foot ulcers by increasing education in developing countries and bringing treatments that will address this global problem to market quickly.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.